Baricitinib decreases anti‑dsDNA in patients with systemic lupus erythematosus: results from a phase II double‑blind, randomized, placebo‑controlled trial
Arthritis Res Ther 2022;24(1):112 doi: 10.1186/s13075-022-02794-x
Previously shown to have therapeutic benefit in SLE in a Phase II study, , Dörner, et al. evaluated the median change from baseline in conventional serologic biomarkers in subgroups, and the overall population, of baricitinib-treated patients with SLE, and the SLE Responder Index-4 response by normalisation of anti-dsDNA.
Their results showed that baricitinib treatment resulted in a rapid and sustained significant decrease in anti-dsDNA antibodies